These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 6198178)

  • 1. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
    Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T
    Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].
    Gawrońska-Szklarz B; Górnik W; Kutrzeba J; Wójcicki J; Zakrzewski J
    Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):921-3. PubMed ID: 1284448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus.
    Reidenberg MM; Drayer DE
    Angiology; 1986 Dec; 37(12 Pt 2):968-71. PubMed ID: 2433971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
    Sonnhag C; Karlsson E; Hed J
    Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic acetylation procainamide in man.
    Reidenberg MM; Drayer DE; Levy M; Warner H
    Clin Pharmacol Ther; 1975 Jun; 17(6):722-30. PubMed ID: 237647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype.
    Gibson TP; Matusik J; Matusik E; Nelson HA; Wilkinson J; Briggs WA
    Clin Pharmacol Ther; 1975 Apr; 17(4):395-9. PubMed ID: 1122681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.
    Coyle JD; Boudoulas H; Lima JJ
    Biopharm Drug Dispos; 1991 Nov; 12(8):599-612. PubMed ID: 1724922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Acetylprocainamide levels in patients with end-stage renal failure.
    Gibson TP; Matusik EJ; Briggs WA
    Clin Pharmacol Ther; 1976 Feb; 19(2):206-12. PubMed ID: 1261157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between the metabolism of procainamide and sulfamethazine.
    Giardina E-GV ; Stein RM; Bigger JT
    Circulation; 1977 Feb; 55(2):388-94. PubMed ID: 832354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of procainamide and N-acetylprocainamide in renal failure.
    Gibson TP; Atkinson AJ; Matusik E; Nelson LD; Briggs WA
    Kidney Int; 1977 Dec; 12(6):422-9. PubMed ID: 609192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of coadministration of procainamide and isoniazid on each other's acetylation pathway.
    Schneck DW; Sprouse JS; Shiroff RA; Vary JE; DeWitt FO; Hayes AH
    Pharmacology; 1979; 18(1):34-41. PubMed ID: 419159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.
    Giardina EG
    Ann N Y Acad Sci; 1984; 432():177-88. PubMed ID: 6084435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.
    Dutcher JS; Strong JM; Lucas SV; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1977 Oct; 22(4):447-57. PubMed ID: 902457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans.
    Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ
    J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
    Woosley RL; Drayer DE; Reidenberg MM; Nies AS; Carr K; Oates JA
    N Engl J Med; 1978 May; 298(21):1157-9. PubMed ID: 306574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.
    Lima JJ; Conti DR; Goldfarb AL; Tilstone WJ; Golden LH; Jusko WJ
    J Pharmacokinet Biopharm; 1979 Feb; 7(1):69-85. PubMed ID: 458558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.